ArticleAACE endocrinology and diabetes

Trends in Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon‑Like Peptide‑1 Receptor Agonist Prescription Rates Among Patients With Type 2 Diabetes: An Epic Cosmos Real-World Data Analysis, 2014-2024.

Donglan S Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.